MGMT and central nervous system cancer: The impact of glioma reclassification based on molecular profiling has subsequently been studied and 3 genetic alterations have been extensively validated: O-6-methylguanine-DNA methyltransferase (MGMT), isocitrate dehydrogenase (IDH), and 1p/19q co-deletion status.1